| 4SG Stock | | | EUR 0.49 0.02 4.26% |
Insider
Hani Lerman is Director of SOL GEL TECHN IS 10
| Age | 46 |
| Phone | 972 8 931 3433 |
| Web | http://www.sol-gel.com |
SOL GEL Management Efficiency
The company has return on total asset
(ROA) of
0.0471 % which means that it generated a profit of $0.0471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1101 %, meaning that it generated $0.1101 on every $100 dollars invested by stockholders. SOL GEL's management efficiency ratios could be used to measure how well SOL GEL manages its routine affairs as well as how well it operates its assets and liabilities.
SOL GEL TECHN IS 10 has accumulated 1.61
M in total debt with debt to equity ratio
(D/E) of 0.04, which may suggest the company is not taking enough advantage from borrowing. SOL GEL TECHN has a current ratio of 7.86, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist SOL GEL until it has trouble settling it off, either with new capital or with free cash flow. So, SOL GEL's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SOL GEL TECHN sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SOL to invest in growth at high rates of return. When we think about SOL GEL's use of debt, we should always consider it together with cash and equity.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel. SOL GEL operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 65 people. SOL GEL TECHN IS 10 (4SG) is traded on Frankfurt Exchange in Germany and employs 53 people.
Management Performance
SOL GEL TECHN Leadership Team
Elected by the shareholders, the SOL GEL's board of directors comprises two types of representatives: SOL GEL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SOL. The board's role is to monitor SOL GEL's management team and ensure that shareholders' interests are well served. SOL GEL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SOL GEL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shmuel Zvi, Independent Director | |
| Nissim Bilman, Vice President - Quality | |
| Dubi Zamir, Vice President - Special Projects | |
| Hani Lerman, Director | |
| Itzik Yosef, Vice President - Operations | |
| Yaffa KrindelSieradzki, Independent Director | |
| Gilad Mamlok, Chief Financial Officer | |
| Itai Arkin, Director | |
| John Vieira, U.S. Head of Commercialization | |
| Alon SeriLevy, Chief Executive Officer, Co-Founder, Director | |
| Karine Neimann, Vice President - Projects and Planning, Chief Chemist | |
| Ran Gottfried, Independent Director | |
| Jonathan Siegel, Independent Director | |
| Ofer Toledano, Vice President - Research & Development | |
| Jerrold Gattegno, Independent Director | |
| Moshe Arkin, Chairman of the Board | |
| Ofra LevyHacham, Vice President - Clinical and Regulatory Affairs | |
SOL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SOL GEL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in SOL Stock
SOL GEL financial ratios help investors to determine whether SOL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SOL with respect to the benefits of owning SOL GEL security.